Palbociclib for HR+ isolated local or regional recurrence of breast cancer
Adjuvant palbociclib in elderly patients with breast cancer
Comparison of adjuvant anti PD-L1 antibody (atezolizumab) plus chemotherapy versus chemotherapy alone in TNBC patients
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy
Aiming to understand the molecular aberrations in metastatic breast cancer
Palbociclib in molecularly characterised ER-positive/HER2-negative metastatic breast cancer
PALbociclib CoLlaborative Adjuvant Study: A randomised phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor pos...
Testing different post-operative endocrine treatments for young women with hormone-sensitive breast cancer
Can addition of 70-gene signature to common clinical-pathological criteria safely spare patients from adjuvant chemotherapy?
EXamining PErsonalised Radiation Therapy for low-risk early breast cancer
Clinical and Biological Characterization of Male Breast Cancer
Comparison of dual HER2 inhibition (lapatinib, trastuzumab) plus chemotherapy before surgery versus single HER2-targeted therapy
ClinicalTrials.gove Identifier: NCT02997995
Different regimes of letrozole (or letrozole + taselisib) in postmenopausal women with ER positive/HER2-negative, early stage breast cancer
Olaparib as adjuvant treatment in patients with germline BRCA mutated high-risk HER2-negative primary breast cancer
Comparison of single-versus-dual anti-HER2 therapy (trastuzumab, pertuzumab) for patients with HER2-positive primary breast cancer
A global hunt for Exceptional Responders in the BIG network
ClinicalTrials.gov Identifier: NCT01548677
Adjuvant lapatinib and trastuzumab: sequence and combination for patients with HER2/ErbB2 positive primary breast cancer
Comparison of different regimes of trastuzumab for women with HER2-positive primary breast cancer
A randomized phase III study of radiation doses and fractionation schedules in non-low risk Ductal Carcinoma In Situ (DCIS) of the breast
Short (9 weeks) versus long (1 year) treatments of early HER2-positive breast cancer with trastuzumab
Letrozole or tamoxifen in treating postmenopausal women with breast cancer ClinicalTrials.gov Identifier: NCT00004205
Prospective Register Study for Diagnosis and Treatment of Breast Cancer in Pregnancy
ClinicalTrials.gov Identifier: NCT02429427
Post-neoadjuvant palbociblib for patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk
ClinicalTrials.gov Identifier: NCT00174655
ClinicalTrials.gov Identifier: NCT00062400
ClinicalTrials.gov Identifier: NCT01746225
ClinicalTrials.gov Identifier: NCT00072020
ClinicalTrials.gov Identifier: NCT00017095
Anti-PD-1 therapy to reverse trastuzumab resistance in HER2+ metastatic breast cancer
ClinicalTrials.gov Identifier: NCT01816594
ClinicalTrials.gov identifier: NCT00966888
ClinicalTrials.gov Identifier: NCT00003140
ClinicalTrials.gov Identifier: NCT01905592
ClinicalTrials.gov Identifier: NCT00196859
ClinicalTrials.gov Identifier: NCT00038467
Continuous versus intermittent letrozole following endocrine treatment for postmenopausal women with disease-free of hormone-receptor positive, node-positive early stage breast cancer
Oral lucitanib for patients with FGFR1 ER+ metastatic breast cancer
DCIS ClinicalTrials.gov Identifier: NCT00072462 Prevention ClinicalTrials.gov Identifier: NCT00078832
ClinicalTrials.gov Identifier: NCT01101438
Enabling information re-Use by linking clinical REsearch and Care
Integrative Cancer Research Through Innovative Biomedical Infrastructures
TRANSBIG was an international network run by big from 2004 to 2011 to promote translational research
